Lesion dissemination derived from FDG PET/CT predicts outcomes in patients with relapsed/refractory DLBCL treated with Loncastuximab Tesirine in the LOTIS-2 trial-MedSci.cn

Lesion dissemination derived from FDG PET/CT predicts outcomes in patients with relapsed/refractory DLBCL treated with Loncastuximab Tesirine in the LOTIS-2 trial

Kuker, R; Yang, F; Han, SW; Reis, I; Polar, M; Moskowitz, C; Alderuccio, J

JOURNAL OF NUCLEAR MEDICINE, 2023; 64 ():

科室
- - 订阅+
  - 更多科室
工具
服务